Core Viewpoint - Celanese Corporation is conducting tender offers to purchase its senior notes, increasing the maximum tender amount and series cap for the notes due in 2027 and 2028, reflecting strong investor interest and adjustments in financial strategy [1][2][6]. Group 1: Tender Offer Details - The company announced early results indicating valid tenders of $946,106,000 for the 6.665% Senior Notes due 2027 and $675,185,000 for the 6.850% Senior Notes due 2028 [4]. - The maximum tender amount has been increased to $1,200,106,000 for the aggregate principal amount of the notes, and the series cap for the 2028 Notes is set at $254,000,000 [2][6]. - The total consideration for each $1,000 principal amount of the 2027 Notes and 2028 Notes validly tendered will be $1,037.50 and $1,055.00, respectively, including an early tender payment of $50.00 [7]. Group 2: Financial Conditions and Management - The interest rates on the 2027 Notes and 2028 Notes have increased to 7.165% and 7.350%, respectively, reflecting a 0.50% rise from their original stated coupons [4]. - The company has retained BofA Securities as the Lead Dealer Manager and D.F. King as the Information and Tender Agent for the tender offers [9]. - The financing condition for the tender offers has been satisfied, allowing the company to proceed with the purchase of the notes [8]. Group 3: Company Overview - Celanese Corporation is a global leader in chemistry, producing specialty material solutions across major industries, with 2024 net sales reported at $10.3 billion [18]. - The company employs over 11,000 individuals worldwide and is committed to sustainability and community impact [18].

Core Viewpoint - Baxter International Inc. has announced early tender results for cash tender offers for its 2026 and 2027 Notes, with a maximum purchase price of up to $600 million for the 2027 Notes [1][2]. Group 1: Tender Offer Details - The tender offers include the purchase of all 2.600% senior unsecured notes due 2026 and a portion of the 1.915% senior unsecured notes due 2027 [2]. - The total principal amount of the 2026 Notes outstanding is $750 million, with $420.589 million tendered by the early tender date [4]. - For the 2027 Notes, the total outstanding is $1.45 billion, with $1.08866 billion tendered [4]. Group 2: Early Tender Date and Settlement - The early tender date was set for December 3, 2025, at 5:00 p.m. New York City time, after which withdrawal rights expired [3]. - The company plans to make payments for the validly tendered notes on December 8, 2025, which is the early settlement date [4]. Group 3: Total Consideration and Pricing - The total consideration for the notes accepted for purchase will include an early tender payment of $30.00 per $1,000 principal amount and will be determined based on the applicable fixed spread and yield of U.S. Treasury reference securities [5]. - The total consideration will be announced on December 4, 2025, at 10:00 a.m. New York City time [5]. Group 4: Pro Rata Acceptance - Due to the expected exceedance of the maximum tender cap for the 2027 Notes, any tendered 2027 Notes will be accepted on a pro rata basis [6]. - The company does not anticipate accepting any 2027 Notes tendered after the early tender date [6]. Group 5: Conditions and Management - The tender offers are subject to certain conditions, including the financing condition specified in the Offer to Purchase [8]. - Citigroup Global Markets Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC are the dealer managers for the tender offers [9].

Core Points - Bristol Myers Squibb has announced the accepted amounts and pricing terms for its tender offers to purchase outstanding notes, adjusting the maximum aggregate purchase prices for both Pool 1 and Pool 2 Notes [1][2][10] Group 1: Tender Offer Details - The maximum aggregate purchase price for Pool 1 Notes has been decreased to approximately $3.99 billion, while the maximum for Pool 2 Notes has been increased to approximately $3.51 billion [2][10] - All validly tendered Pool 1 Notes and Pool 2 Notes with acceptance priority levels 1 through 4 have been accepted for purchase, eliminating the need for proration procedures for these notes [4][10] - The 2033 Notes will be accepted on a prorated basis due to the total principal amount exceeding $250 million [4][10] Group 2: Financial Terms - The Total Consideration for each series of Notes accepted for purchase will be paid in cash, excluding accrued and unpaid interest up to the Early Settlement Date [11][12] - The Offers will expire on December 3, 2025, unless extended or terminated earlier, with the Early Settlement Date set for November 20, 2025 [10][11] Group 3: Participation and Acceptance - The withdrawal rights for the Offers expired on November 17, 2025, and all conditions of the Offers were satisfied or waived by the Early Tender Deadline [10][11] - Holders of Notes that are accepted for purchase will receive the applicable Total Consideration, while those not accepted will have their notes returned promptly [4][11]